Platelet-rich plasma (PRP) represents a promising autologous biologic therapy that has transformed approaches to soft tissue regeneration across multiple medical specialties. This autologous blood-derived concentrate contains supraphysiological concentrations of platelets and their associated growth factors, which orchestrate critical healing processes. The therapeutic rationale of PRP lies in its ability to amplify natural wound healing cascades by delivering concentrated bioactive molecules directly to injury sites, thereby enhancing angiogenesis, cellular proliferation, extracellular matrix synthesis, and tissue remodeling. The clinical applications of PRP have expanded rapidly from their origins in maxillofacial surgery to encompass musculoskeletal injuries, dermatologic conditions, wound healing, and aesthetic procedures. PRP demonstrates particular promise for tendinopathies, ligament injuries, muscle strains, chronic wounds, and scar management, where conventional therapies often provide suboptimal outcomes. The preparation methodology involves centrifugation-based platelet concentration, with various protocols yielding different cellular compositions that significantly influence therapeutic efficacy. Despite widespread clinical adoption, PRP therapy faces several challenges, including variable preparation methods, inconsistent clinical outcomes, a lack of standardization, and a limited understanding of optimal dosing protocols. Current evidence supports the safety profile and biological rationale of PRP, with studies demonstrating accelerated healing, reduced inflammation, and improved tissue quality in various soft tissue applications. Future innovations focus on combination therapies, personalized formulations, controlled-release systems, and integration with biomaterials to optimize therapeutic potential. As regenerative medicine continues evolving, PRP remains a valuable tool for soft tissue repair, offering a minimally invasive, autologous approach that harnesses the body’s intrinsic healing mechanisms.